CoChat

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Open access
Levin, Philip A, Nguyen, Hiep, Wittbrodt, Eric, Kim, Seoyoung C. · 2017 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety. OBJECTIVE: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed. METHODS: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D. RESULTS: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings. CONCLUSION: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s130834

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram. Abbreviation: GLP-1RA, glucagon-like peptide-1 receptor agonist.
Figure 1 PRISMA flow diagram. Abbreviation: GLP-1RA, glucagon-like peptide-1 receptor agonist.CC BY-NC · PubMed Central
Figure 2 Efficacy of glucose-lowering treatments in type 2 diabetes. Changes from baseline in (A) glycated hemoglobin (HbA1c), (B) fasting glucose (FG), and (C) body weight (BW) in prospective studies comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) with other oral glucose-lowering therapies and changes from baseline in (D) HbA1c, (E) FG, and (F) BW in prospective studies comparing GLP-1RAs with insulin products. Abbreviation: DPP-4, dipeptidyl peptidase-4.
Figure 2 Efficacy of glucose-lowering treatments in type 2 diabetes. Changes from baseline in (A) glycated hemoglobin (HbA1c), (B) fasting glucose (FG), and (C) body weight (BW) in prospective studies comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) with other oral glucose-lowering therapies and changes from baseline in (D) HbA1c, (E) FG, and (F) BW in prospective studies comparing GLP-1RAs with insulin products. Abbreviation: DPP-4, dipeptidyl peptidase-4.CC BY-NC · PubMed Central
Figure 3 Comparison of efficacy of GLP-1RAs with other glucose-lowering treatments in type 2 diabetes. General trends in glycemic parameters and body weight (BW) in comparative trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other glucose-lowering therapies. The total number of studies includes studies that reported these parameters. Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; FG, fasting glucose; HbA1c, glycated hemoglobin; SU, sulfonylurea; TZD, thiazolidinedione.
Figure 3 Comparison of efficacy of GLP-1RAs with other glucose-lowering treatments in type 2 diabetes. General trends in glycemic parameters and body weight (BW) in comparative trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other glucose-lowering therapies. The total number of studies includes studies that reported these parameters. Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; FG, fasting glucose; HbA1c, glycated hemoglobin; SU, sulfonylurea; TZD, thiazolidinedione.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Cited by

Items 101–106 of 106

Metadata

Authors
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C.
Affiliations
  • AstraZeneca (United States) (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Kim, Seoyoung C.
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2017-04
Volume
Volume 10
Pages
123-139
ISSN
1178-7007 (ISSN-L)
OpenAlex
W2604317643
Cited by
107
References
78
Citations by year
2026: 7 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 10 · 2021: 15 · 2020: 19 · 2019: 18 · 2018: 14 · 2017: 1
FWCI
2.07
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, comparative effectiveness, glycemic control, HbA1c, insulin therapy, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, metformin, weight loss, hypoglycemia, cardiovascular outcomes, exenatide, dulaglutide, liraglutide, lixisenatide, albiglutide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.